Cargando…

Lasofoxifene as a potential treatment for therapy-resistant ER-positive metastatic breast cancer

BACKGROUND: Endocrine therapy remains the mainstay of treatment for estrogen receptor-positive (ER+) breast cancer. Constitutively active mutations in the ligand binding domain of ERα render tumors resistant to endocrine agents. Breast cancers with the two most common ERα mutations, Y537S and D538G,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lainé, Muriel, Fanning, Sean W., Chang, Ya-Fang, Green, Bradley, Greene, Marianne E., Komm, Barry, Kurleto, Justyna D., Phung, Linda, Greene, Geoffrey L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8117302/ https://www.ncbi.nlm.nih.gov/pubmed/33980285 http://dx.doi.org/10.1186/s13058-021-01431-w

Ejemplares similares

SUN-006 Lasofoxifene Achieves Potent Anti-Tumor Activity in Hormone-Resistant Breast Tumors by Maintaining High Affinity Binding for Y537S ERα
por: Fanning, Sean, et al.
Publicado: (2019)

Stereospecific lasofoxifene derivatives reveal the interplay between estrogen receptor alpha stability and antagonistic activity in ESR1 mutant breast cancer cells
por: Hosfield, David J, et al.
Publicado: (2022)

Lasofoxifene for the prevention and treatment of postmenopausal osteoporosis
por: Lewiecki, E Michael
Publicado: (2009)

Lasofoxifene: Evidence of its therapeutic value in osteoporosis
por: Gennari, Luigi, et al.
Publicado: (2010)

Effects of lasofoxifene and bazedoxifene on B cell development and function
por: Bernardi, Angelina I, et al.
Publicado: (2014)

Synthesis of Lasofoxifene, Nafoxidine and Their Positional Isomers via the Novel Three-Component Coupling Reaction
por: Nakata, Kenya, et al.
Publicado: (2010)

THU546 A Lasofoxifene/Elacestrant Hybrid Antiestrogen Shows Effective Anti-tumoral Activities In Y537S ESR1 Breast Cancer Xenografts
por: Young, Kristen S, et al.
Publicado: (2023)

RAC3 is a promigratory co-activator of ERα
por: Walker, Matthew P, et al.
Publicado: (2011)

Selective estrogen receptor modulator (SERM) for the treatment of osteoporosis in postmenopausal women: focus on lasofoxifene
por: Gennari, Luigi, et al.
Publicado: (2010)

Unconventional isoquinoline-based SERMs elicit fulvestrant-like transcriptional programs in ER+ breast cancer cells
por: Hancock, G. R., et al.
Publicado: (2022)

Selective oestrogen receptor modulators lasofoxifene and bazedoxifene inhibit joint inflammation and osteoporosis in ovariectomised mice with collagen-induced arthritis
por: Andersson, Annica, et al.
Publicado: (2016)

ERα/PR crosstalk is altered in the context of the ERα Y537S mutation and contributes to endocrine therapy-resistant tumor proliferation
por: Huggins, Rosemary J., et al.
Publicado: (2023)

Selective estrogen receptor modulator lasofoxifene suppresses spondyloarthritis manifestation and affects characteristics of gut microbiota in zymosan-induced SKG mice
por: Jeong, Hyemin, et al.
Publicado: (2021)

THU554 Unconventional Estrogen Receptor Antagonists Reveal Cryptic Therapeutic Anti-breast Cancer Transcriptional Pathways
por: Hancock, Govinda, et al.
Publicado: (2023)

Mapping ERβ Genomic Binding Sites Reveals Unique Genomic Features and Identifies EBF1 as an ERβ Interactor
por: Le, Thien P., et al.
Publicado: (2013)

Genomic agonism and phenotypic antagonism between estrogen and progesterone receptors in breast cancer
por: Singhal, Hari, et al.
Publicado: (2016)

Targeting AKT in ER-Positive HER2-Negative Metastatic Breast Cancer: From Molecular Promises to Real Life Pitfalls?
por: Mery, Benoîte, et al.
Publicado: (2021)

Selective pressure of endocrine therapy activates the integrated stress response through NFκB signaling in a subpopulation of ER positive breast cancer cells
por: Semina, Svetlana E., et al.
Publicado: (2022)

Progesterone receptor isoforms, agonists and antagonists differentially reprogram estrogen signaling
por: Singhal, Hari, et al.
Publicado: (2017)

Dynamic epi‐transcriptomic landscape mapping with disease progression in estrogen receptor‐positive breast cancer
por: Keelan, Stephen, et al.
Publicado: (2023)

Super-enhancer-controlled positive feedback loop BRD4/ERα–RET–ERα promotes ERα-positive breast cancer
por: Zheng, Zao-zao, et al.
Publicado: (2022)

The pioneer factor PBX1 is a novel driver of metastatic progression in ERα-positive breast cancer
por: Magnani, Luca, et al.
Publicado: (2015)

Isolation and Characterization of a Metastatic Hybrid Cell Line Generated by ER Negative and ER Positive Breast Cancer Cells in Mouse Bone Marrow
por: Mukhopadhyay, Keya De, et al.
Publicado: (2011)

Estrogens Correlate with PELP1 Expression in ER Positive Breast Cancer
por: Flågeng, Marianne Hauglid, et al.
Publicado: (2015)

Circulating tumor cell number and endocrine therapy index in ER positive metastatic breast cancer patients
por: Paoletti, Costanza, et al.
Publicado: (2021)

Glucocorticoid receptor modulation decreases ER-positive breast cancer cell proliferation and suppresses wild-type and mutant ER chromatin association
por: Tonsing-Carter, Eva, et al.
Publicado: (2019)

ESR1 ligand binding domain mutations in hormone-resistant breast cancer
por: Toy, Weiyi, et al.
Publicado: (2013)

Targeting estrogen to kill ER-positive and ER-negative breast cancer
por: Jordan, VC
Publicado: (2005)

Family of neural wiring receptors in bilaterians defined by phylogenetic, biochemical, and structural evidence
por: Cheng, Shouqiang, et al.
Publicado: (2019)

Heterogeneity and clinical significance of ESR1 mutations in ER-positive metastatic breast cancer patients receiving fulvestrant
por: Spoerke, Jill M., et al.
Publicado: (2016)

MYC Targets Scores Are Associated with Cancer Aggressiveness and Poor Survival in ER-Positive Primary and Metastatic Breast Cancer
por: Schulze, Amy, et al.
Publicado: (2020)

Selective AKT kinase inhibitor capivasertib in combination with fulvestrant in PTEN-mutant ER-positive metastatic breast cancer
por: Smyth, Lillian M., et al.
Publicado: (2021)

ER and PI3K Pathway Activity in Primary ER Positive Breast Cancer Is Associated with Progression-Free Survival of Metastatic Patients under First-Line Tamoxifen
por: M. Sieuwerts, Anieta, et al.
Publicado: (2020)

Glucocorticoid Receptor Activation in Lobular Breast Cancer Is Associated with Reduced Cell Proliferation and Promotion of Metastases
por: Porter, Baylee A., et al.
Publicado: (2023)

Defining the Energetic Basis for a Conformational Switch Mediating Ligand-Independent Activation of Mutant Estrogen Receptors in Breast Cancer
por: Mayne, Christopher G., et al.
Publicado: (2021)

Estrogen receptor alpha somatic mutations Y537S and D538G confer breast cancer endocrine resistance by stabilizing the activating function-2 binding conformation
por: Fanning, Sean W, et al.
Publicado: (2016)

RCC2 Expression Stimulates ER-Positive Breast Tumorigenesis
por: Wang, Weiqi, et al.
Publicado: (2020)

Degree of Early Estrogen Response Predict Survival after Endocrine Therapy in Primary and Metastatic ER-Positive Breast Cancer
por: Oshi, Masanori, et al.
Publicado: (2020)

Molecular basis of synaptic specificity by immunoglobulin superfamily receptors in Drosophila
por: Cheng, Shouqiang, et al.
Publicado: (2019)

Targeted therapies for ER+/HER2- metastatic breast cancer
por: Yamamoto-Ibusuki, Mutsuko, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_o4eb5gi3650f7ab7ic04tubrts